GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Price-to-Owner-Earnings

Zealand Pharma A/S (Zealand Pharma A/S) Price-to-Owner-Earnings : (As of May. 21, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Price-to-Owner-Earnings?

As of today (2024-05-21), Zealand Pharma A/S's share price is $90.70. Zealand Pharma A/S does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Zealand Pharma A/S's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Zealand Pharma A/S was 83.68. The lowest was 2.94. And the median was 7.54.


ZLDPF's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.465
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-21), Zealand Pharma A/S's share price is $90.70. Zealand Pharma A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.84. Therefore, Zealand Pharma A/S's PE Ratio for today is At Loss.

As of today (2024-05-21), Zealand Pharma A/S's share price is $90.70. Zealand Pharma A/S's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.18. Therefore, Zealand Pharma A/S's PE Ratio without NRI for today is At Loss.

During the past 13 years, Zealand Pharma A/S's highest PE Ratio without NRI was 10.33. The lowest was 0.00. And the median was 6.49.


Zealand Pharma A/S Price-to-Owner-Earnings Historical Data

The historical data trend for Zealand Pharma A/S's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Price-to-Owner-Earnings Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zealand Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zealand Pharma A/S's Price-to-Owner-Earnings

For the Biotechnology subindustry, Zealand Pharma A/S's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Price-to-Owner-Earnings falls into.



Zealand Pharma A/S Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Zealand Pharma A/S's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=90.70/-2.83
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zealand Pharma A/S  (OTCPK:ZLDPF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Zealand Pharma A/S Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.